Your browser doesn't support javascript. This means that the content or functionality of our website will be limited or unavailable. If you need more information about Vinnova, please contact us.

Cellda Prostate for cancer diagnosis - regulatory and market evaluation

Reference number
Coordinator Cellda AB
Funding from Vinnova SEK 121 500
Project duration September 2024 - July 2025
Status Ongoing
Venture Medtech4Health: Competence Enhancement in SME
Call Medtech4Health: Competence Enhancement in Small Businesses 2024

Important results from the project

The project objectives have been met. European markets for Cellda® Prostate have been evaluated, prioritized and a basis has been created for continued development of the project and the company. The regulatory strategy has been developed and a clinical performance study has been conducted. The overall result is that the project has contributed to the development and implementation of Cellda® Prostate.

Expected long term effects

The project is expected to have long-term effects by increasing Cellda´s expertise in regulatory issues and market evaluation, allowing the company to work more independently with the goal of obtaining certification for Cellda® Prostate and clinical implementation in prioritized markets. The company has gained new knowledge that can be applied to new development projects in the future and thus create more products.

Approach and implementation

Hired consultants and experts have worked together with the company´s operational team to implement the project. Joint project meetings to identify tasks, plan and follow up activities, and report. The project manager has ensured that the project´s implementation, results and conclusions have been documented and implemented.

External links

The project description has been provided by the project members themselves and the text has not been looked at by our editors.

Last updated 15 August 2025

Reference number 2024-02092